skyrizi efficacy still wins. staying on the data.

Company: AbbVie

Posted by SkyriziRep_IL_2234 · March 18, 2026

Tags: field, strategy, launch

PASI 90/100 is still class leading.

pill is convenient.

doesnt mean it works better.

thats my story and im not moving off it.

11 upvotes · 4 comments

More from AbbVie